|
2.6 Etiologie - Environnement
|
|
|
|
5.2 Pharma
|
|
|
|
5.3 Traitements - FDA, EMA,...
|
|
|
The life and legacy of oncology PROMs [BMJ Blogs]
|
|
|
|
|
|
The
FDA is right to set standards high in terms of the “quality” of Patient
Reported Outcomes Measures (PROMs); however by ignoring ongoing
patient validation of legacy instruments and starting from scratch with
tool development, are we at risk of throwing out the baby with the
bathwater?
|
|
|
|
|
|
|
5.4 Traitements - Economie
|
|
|
|
NICE publishes draft guidance for two prostate cancer treatments [NICE]
|
|
|
|
|
|
-
NICE is recommending radium-223 dichloride (also called Xofigo) as a
treatment for some people with prostate cancer which has stopped
responding to hormone therapy (known as hormone relapsed) and has spread
to the bone (bone metastases). - Meanwhile, NICE has issued draft
guidance not recommending degarelix depot - also called Firmagon and
manufactured by Ferring Pharmaceuticals - to treat advanced, hormone
dependent prostate cancer.
|
|
|
|
|
|
|
|
5.5.1 ASCO (général)
|
|
|
|
|
6. Lutte contre les cancers
|
|
|
|
6.1 Observation
|
|
|
|
|
6.11 Patients
|
|
|
|
6.4 Médico-éco
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|